Cargando…
Aromatase inhibitor–associated musculoskeletal pain: An overview of pathophysiology and treatment modalities
Since their introduction into clinical use in the 1970s, aromatase inhibitors have been a cornerstone of therapy for estrogen-receptor positive breast cancer in postmenopausal women. Unfortunately, this therapy leads to estrogen depletion in the body, which can lead to unpleasant side effects such a...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935546/ https://www.ncbi.nlm.nih.gov/pubmed/35321462 http://dx.doi.org/10.1177/20503121221078722 |
_version_ | 1784672055540580352 |
---|---|
author | Grigorian, Nelly Baumrucker, Steven J |
author_facet | Grigorian, Nelly Baumrucker, Steven J |
author_sort | Grigorian, Nelly |
collection | PubMed |
description | Since their introduction into clinical use in the 1970s, aromatase inhibitors have been a cornerstone of therapy for estrogen-receptor positive breast cancer in postmenopausal women. Unfortunately, this therapy leads to estrogen depletion in the body, which can lead to unpleasant side effects such as menopausal symptoms like hot flashes, insomnia, slightly increased risk of ischemic heart disease, accelerated bone loss leading to higher osteoporosis risk, and most significantly, arthralgias. The joint pain induced by aromatase inhibitor therapy is frequently cited as the leading cause of premature discontinuation; approximately 50% of patients will report new onset or worsening joint pain 1 year after therapy initiation, approximately 30% of patients discontinue therapy after 1 year, and only 50%–68% of patients remain fully compliant with therapy after 3 years. This article will describe risk factors for aromatase inhibitor–associated musculoskeletal syndrome, including genetic predispositions correlated with an increased risk of this syndrome, explain the currently understood pathophysiology, and give an overview of effective treatment options in managing this syndrome. |
format | Online Article Text |
id | pubmed-8935546 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-89355462022-03-22 Aromatase inhibitor–associated musculoskeletal pain: An overview of pathophysiology and treatment modalities Grigorian, Nelly Baumrucker, Steven J SAGE Open Med Review Since their introduction into clinical use in the 1970s, aromatase inhibitors have been a cornerstone of therapy for estrogen-receptor positive breast cancer in postmenopausal women. Unfortunately, this therapy leads to estrogen depletion in the body, which can lead to unpleasant side effects such as menopausal symptoms like hot flashes, insomnia, slightly increased risk of ischemic heart disease, accelerated bone loss leading to higher osteoporosis risk, and most significantly, arthralgias. The joint pain induced by aromatase inhibitor therapy is frequently cited as the leading cause of premature discontinuation; approximately 50% of patients will report new onset or worsening joint pain 1 year after therapy initiation, approximately 30% of patients discontinue therapy after 1 year, and only 50%–68% of patients remain fully compliant with therapy after 3 years. This article will describe risk factors for aromatase inhibitor–associated musculoskeletal syndrome, including genetic predispositions correlated with an increased risk of this syndrome, explain the currently understood pathophysiology, and give an overview of effective treatment options in managing this syndrome. SAGE Publications 2022-03-19 /pmc/articles/PMC8935546/ /pubmed/35321462 http://dx.doi.org/10.1177/20503121221078722 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Grigorian, Nelly Baumrucker, Steven J Aromatase inhibitor–associated musculoskeletal pain: An overview of pathophysiology and treatment modalities |
title | Aromatase inhibitor–associated musculoskeletal pain: An overview of pathophysiology and treatment modalities |
title_full | Aromatase inhibitor–associated musculoskeletal pain: An overview of pathophysiology and treatment modalities |
title_fullStr | Aromatase inhibitor–associated musculoskeletal pain: An overview of pathophysiology and treatment modalities |
title_full_unstemmed | Aromatase inhibitor–associated musculoskeletal pain: An overview of pathophysiology and treatment modalities |
title_short | Aromatase inhibitor–associated musculoskeletal pain: An overview of pathophysiology and treatment modalities |
title_sort | aromatase inhibitor–associated musculoskeletal pain: an overview of pathophysiology and treatment modalities |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935546/ https://www.ncbi.nlm.nih.gov/pubmed/35321462 http://dx.doi.org/10.1177/20503121221078722 |
work_keys_str_mv | AT grigoriannelly aromataseinhibitorassociatedmusculoskeletalpainanoverviewofpathophysiologyandtreatmentmodalities AT baumruckerstevenj aromataseinhibitorassociatedmusculoskeletalpainanoverviewofpathophysiologyandtreatmentmodalities |